Capstone Investment Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.51M | Buy |
27,800
+7,400
| +36% | +$620K | ﹤0.01% | 672 |
|
|
2026
Q1 | $1.63M | Sell |
20,400
-1,600
| -7% | -$132K | ﹤0.01% | 699 |
|
|
2025
Q4 | $1.88M | Sell |
22,000
-13,900
| -39% | -$1.14M | ﹤0.01% | 650 |
|
|
2025
Q3 | $2.79M | Buy |
35,900
+2,600
| +8% | +$203K | 0.01% | 648 |
|
|
2025
Q2 | $2.6M | Sell |
33,300
-29,600
| -47% | -$2.21M | 0.01% | 563 |
|
|
2025
Q1 | $4.56M | Buy |
62,900
+3,000
| +5% | +$215K | 0.01% | 481 |
|
|
2024
Q4 | $4.43M | Buy |
59,900
+25,900
| +76% | +$1.81M | 0.01% | 597 |
|
|
2024
Q3 | $2.24M | Sell |
34,000
-3,300
| -9% | -$240K | 0.01% | 695 |
|
|
2024
Q2 | $3.45M | Buy |
37,300
+8,700
| +30% | +$770K | 0.01% | 561 |
|
|
2024
Q1 | $2.73M | Sell |
28,600
-38,700
| -58% | -$3.25M | 0.01% | 650 |
|
|
2023
Q4 | $5.13M | Buy |
67,300
+26,500
| +65% | +$1.84M | 0.02% | 516 |
|
|
2023
Q3 | $2.83M | Sell |
40,800
-9,500
| -19% | -$763K | 0.01% | 607 |
|
|
2023
Q2 | $4.74M | Buy |
50,300
+1,300
| +3% | +$113K | 0.02% | 390 |
|
|
2023
Q1 | $4.05M | Buy |
49,000
+31,600
| +182% | +$2.48M | 0.02% | 410 |
|
|
2022
Q4 | $1.3M | Sell |
17,400
-69,400
| -80% | -$5.35M | 0.01% | 848 |
|
|
2022
Q3 | $7.17M | Sell |
86,800
-16,600
| -16% | -$1.6M | 0.04% | 315 |
|
|
2022
Q2 | $9.83M | Sell |
103,400
-65,200
| -39% | -$6.75M | 0.05% | 265 |
|
|
2022
Q1 | $19.8M | Sell |
168,600
-197,700
| -54% | -$22.2M | 0.05% | 260 |
|
|
2021
Q4 | $47.5M | Sell |
366,300
-26,100
| -7% | -$3.04M | 0.08% | 214 |
|
|
2021
Q3 | $44.4M | Buy |
392,400
+22,100
| +6% | +$2.52M | 0.09% | 200 |
|
|
2021
Q2 | $38.4M | Buy |
370,300
+98,400
| +36% | +$9.28M | 0.09% | 203 |
|
|
2021
Q1 | $22.7M | Sell |
271,900
-94,700
| -26% | -$8.01M | 0.07% | 271 |
|
|
2020
Q4 | $33.4M | Sell |
366,600
-17,800
| -5% | -$1.48M | 0.11% | 148 |
|
|
2020
Q3 | $30.7M | Buy |
384,400
+61,800
| +19% | +$4.82M | 0.16% | 115 |
|
|
2020
Q2 | $22.3M | Buy |
322,600
+88,000
| +38% | +$6.25M | 0.15% | 123 |
|
|
2020
Q1 | $14.8M | Sell |
234,600
-184,800
| -44% | -$13.3M | 0.24% | 73 |
|
|
2019
Q4 | $32.6M | Buy |
419,400
+207,900
| +98% | +$16.2M | 0.18% | 124 |
|
|
2019
Q3 | $15.5M | Buy |
211,500
+12,300
| +6% | +$864K | 0.11% | 185 |
|
|
2019
Q2 | $12.3M | Buy |
199,200
+51,300
| +35% | +$3.1M | 0.09% | 240 |
|
|
2019
Q1 | $9.43M | Buy |
147,900
+84,000
| +131% | +$4.79M | 0.09% | 225 |
|
|
2018
Q4 | $3.26M | Buy |
63,900
+6,300
| +11% | +$319K | 0.04% | 342 |
|
|
2018
Q3 | $3.34M | Buy |
+57,600
| New | +$2.82M | 0.04% | 329 |
|
Other funds holding EW
Capstone Investment Advisors's EW Position: Q2 2026 in Review
Capstone Investment Advisors sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 4,024 shares — an estimated $337K sold.
Capstone Investment Advisors first reported a position in EW in Q4 2015 and held it in 31 quarters. The position peaked at $4.19M in Q3 2022. 1,337 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Capstone Investment Advisors reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
- Capstone Investment Advisors sold 4,024 Edwards Lifesciences shares in Q2 2026, an estimated $337K.
- Capstone Investment Advisors first reported a position in Edwards Lifesciences in Q4 2015 and held it in 31 quarters.
- Capstone Investment Advisors's Edwards Lifesciences position peaked at $4.19M in Q3 2022.
- 1,337 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.